RE:RE:RE:Katama Factsheet cachedOn the right side of the doc they also talk about what proceeds would be used for so resumably that doc was used for finance raising. Dont know if they succeeded or failed. If this is essentially the same team thats at Angiochem it could represent them focussing on that as it approaches some important milestones. But you're right, can't ignore the basic valuation here, but you can't always relate a commercial deadend for an organization with a clinical deadend for the projects. It does seem like theratech is inheriting their setup at UQAM which I'm assuming is connected in some way to Beliveau's research group there. In the cc this morning beliveau was gushing about the work they plan to publish this year on the biodistribution of the drug.
palinc2000 wrote: It appears from the fact sheet that they have been looking to partner with oharmas with propietary molecules...That did not work out...
So they are basically selling all their research for 2 million dollrs now plus maybe another 900k if subsidies are received,,,,,,and maybe nothing else if they dont achieve the milestones in 2 -3 years from now
Moreover all they are getting from TH is cash ,,,,,nothing else
I dont think you need to be a scientist to think that maybe their belief in success is not great .
PoorOpinion wrote: How would you read todays deal from Katana's perspective?
Beliveau is connected with Angiochem which focuses on peptides that cross the blood brain barrier and has oncology drugs in phase III.